Study guide
5.3 Growth Factors & Extracellular Matrix (ECM)
ABWM Certified Wound Specialist CWS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the ABWM CWS Exam 1.2 How to Use This Study Guide & Blueprint Strategy
2 Chapter 2: Comprehensive Patient & Wound Assessment
2.1 Patient History & Systemic Risk Factors 2.2 Physical Examination & Anatomical Wound Classification 2.3 Quantitative Wound Measurement & Documentation 2.4 Bioburden & Infection Assessment
3 Chapter 3: Vascular Assessment & Diagnostic Testing
Section 3.1: Ankle-Brachial Index (ABI) & Toe-Brachial Index (TBI) Interpretation Section 3.2: Advanced Vascular Diagnostics Section 3.3: Neuropathic & Sensory Assessment
4 Chapter 4: Laboratory, Imaging & Diagnostic Approaches
Section 4.1: Laboratory Evaluation in Wound Care Section 4.2: Imaging Modalities for Wounds & Bone Section 4.3: Differential Diagnosis of Recalcitrant & Atypical Wounds
5 Chapter 5: Physiology of Wound Healing & Tissue Repair
5.1 Hemostasis & Inflammatory Phase Dynamics 5.2 Proliferative & Remodeling Phases 5.3 Growth Factors & Extracellular Matrix (ECM)
6 Chapter 6: Biofilm Biology & Wound Bed Preparation
6.1 Biofilm Pathophysiology & Management Strategies 6.2 TIME Framework & Wound Bed Preparation 6.3 Moisture Balance & Exudate Management
7 Chapter 7: Pressure Injuries & Moisture-Associated Skin Damage
7.1 Pressure Injury Pathophysiology & NPIAP Staging 7.2 Risk Assessment Tools & Support Surface Selection 7.3 Moisture-Associated Skin Damage (MASD) & Incontinence-Associated Dermatitis
8 Chapter 8: Lower Extremity Ulcers (Venous, Arterial & Mixed)
Section 8.1: Venous Leg Ulcers & CEAP Classification Section 8.2: Arterial Ulcers & Peripheral Artery Disease Section 8.3: Mixed Venous-Arterial Ulcers & Lymphedema
9 Chapter 9: Diabetic Foot Ulcers & Neuropathic Wounds
Section 9.1: Diabetic Foot Ulcer Pathophysiology & Classification Section 9.2: Diabetic Foot Infection & Osteomyelitis Management
10 Chapter 10: Thermal Injuries, Surgical Wounds & Special Etiologies
Section 10.1: Burn Injuries & Thermal Damage Section 10.2: Surgical Wounds, Dehisced Incisions & Fistulas Section 10.3: Dermatological, Pediatric & Miscellaneous Wound Types
11 Chapter 11: Debridement & Topically Applied Therapies
Section 11.1: Debridement Modalities & Selection Section 11.2: Wound Dressing Selection & Categories Section 11.3: Topical Antimicrobial Agents & Antiseptics
12 Chapter 12: Compression Therapy & Advanced Off-Loading
Section 12.1: Compression Therapy Modalities & Science Section 12.2: Off-Loading Devices & Biomechanical Protection
13 Chapter 13: Advanced & Adjunctive Wound Therapies
Section 13.1: Negative Pressure Wound Therapy (NPWT) Section 13.2: HBOT, Biophysical Agents & Advanced Biologics Section 13.3: Systemic Nutrition, Hydration & Pain Management
14 Chapter 14: Professional Practice, Reimbursement & Interprofessional Care
14.1 Professional Ethics, Scope of Practice & ABWM Guidelines 14.2 Documentation, Coding & Reimbursement Standards 14.3 Interprofessional Team Roles & Quality Improvement
5.3 Growth Factors & Extracellular Matrix (ECM)
Key Takeaways Explain This Topic AI
Growth factors function as molecular signaling cytokines (PDGF, VEGF, FGF, TGF-beta, EGF) regulating cell proliferation, chemotaxis, differentiation, and matrix synthesis.
The Extracellular Matrix (ECM) provides structural scaffolding and cell-signaling cues composed of collagen, fibronectin, hyaluronic acid, proteoglycans, and elastin.
Matrix Metalloproteinases (MMPs) are zinc-dependent endopeptidases that degrade ECM components, while Tissue Inhibitors of Metalloproteinases (TIMPs) regulate MMP activity in balanced tissue turnover.
In chronic non-healing wounds, a pathologically elevated MMP-to-TIMP ratio results in rapid degradation of beneficial ECM proteins and therapeutic growth factors.
Elevated inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) in chronic wound fluid maintain high MMP levels and prevent the transition to the proliferative healing phase.
Last updated: July 2026
Growth Factors & Extracellular Matrix (ECM)
The progression of wound healing relies upon precise biochemical signaling between soluble cytokines—specifically Growth Factors —and the structural microenvironment known as the Extracellular Matrix (ECM) . In healthy tissue repair, a delicate equilibrium exists between matrix degradation and matrix synthesis, regulated by Matrix Metalloproteinases (MMPs) and their endogenous counter-regulators, Tissue Inhibitors of Metalloproteinases (TIMPs) . A key focus of the CWS examination is understanding how this biochemical balance fails in chronic non-healing wounds.
1. Key Growth Factors in Tissue Repair
Growth Factors are biologically active polypeptides that bind to specific transmembrane cell surface receptors, triggering intracellular signaling cascades that direct cell migration (chemotaxis), proliferation (mitogenesis), differentiation, and protein synthesis. KEY GROWTH FACTORS IN WOUND HEALING
- ┌──────────┬──────────────────────────────────────────────────────────────┐
- │ Factor │ Primary Cellular Sources & Clinical Functions │
- ├──────────┼──────────────────────────────────────────────────────────────┤
- │ PDGF │ Platelets, Macrophages. Recruits PMNs, monocytes & │
- │ │ fibroblasts; initiates granulation tissue deposition. │
- ├──────────┼──────────────────────────────────────────────────────────────┤
- │ VEGF │ Endothelial cells, Macrophages. Primary driver of │
- │ │ angiogenesis & vascular permeability. │
- ├──────────┼──────────────────────────────────────────────────────────────┤
- │ FGF │ Fibroblasts, Endothelial cells. bFGF drives angiogenesis; │
- │ │ KGF (FGF-7) stimulates keratinocyte re-epithelialization. │
- ├──────────┼──────────────────────────────────────────────────────────────┤
- │ TGF-β │ Platelets, Macrophages, T-cells. Stimulates collagen │
- │ │ synthesis & myofibroblasts; inhibits MMP degradation. │
- ├──────────┼──────────────────────────────────────────────────────────────┤
- │ EGF │ Platelets, Salivary/Submaxillary glands. Accelerates │
- │ │ keratinocyte division & epidermal resurfacing. │
- └──────────┴──────────────────────────────────────────────────────────────┘
- Platelet-Derived Growth Factor (PDGF)
Primary Sources : Platelet alpha-granules, macrophages, endothelial cells, smooth muscle cells.
Functions : Potent chemoattractant for neutrophils, macrophages, and fibroblasts. Stimulates fibroblast proliferation and early ECM synthesis.
Clinical Application : Recombinant human PDGF-BB ( Becaplermin / Regranex ) is an FDA-approved topical growth factor indicated for neuropathic diabetic foot ulcers extending into subcutaneous tissue with adequate vascular supply.
Vascular Endothelial Growth Factor (VEGF)
Primary Sources : Macrophages, keratinocytes, fibroblasts, endothelial cells under hypoxic stress.
Functions : Specific mitogen for vascular endothelial cells. Induces microvascular permeability and capillary sprout formation during proliferation.
Fibroblast Growth Factor (FGF) Family
basic FGF (bFGF / FGF-2) : Stimulates angiogenesis, endothelial sprouting, and fibroblast proliferation.
Keratinocyte Growth Factor (KGF / FGF-7) : Exclusively acts on epithelial cells; accelerates keratinocyte migration and proliferation across open epidermal deficits.
Transforming Growth Factor-Beta (TGF-β)
Primary Sources : Platelets, M2 macrophages, T-lymphocytes.
Functions : Key master regulator of collagen synthesis. It stimulates fibroblasts to produce Types I and III collagen, promotes myofibroblast differentiation for wound contraction, and downregulates MMP production while upregulating TIMPs.
Pathology : Overexpression of TGF-β1 is strongly implicated in fibrotic disease, hypertrophic scars, and keloids.
Epidermal Growth Factor (EGF) and TGF-α
Functions : Bind to the EGF receptor (EGFR) on keratinocytes and endothelial cells, accelerating re-epithelialization and epidermal restoration.
2. Extracellular Matrix (ECM) Components
The ECM is not merely an inert structural filler; it is a dynamic, instructive 3D microenvironment that modulates cell adhesion, migration, signaling, and mechanical integrity. EXTRACELLULAR MATRIX
- │
- ┌──────────────────────────┼──────────────────────────┐
- ▼ ▼ ▼
- Structural Cell Adhesive Proteoglycans &
- Proteins Glycoproteins Glycosaminoglycans
- (Collagen I, III, IV; (Fibronectin, Laminin, (Hyaluronic Acid, Decorin,
- Elastin) Vitronectin) Heparan Sulfate)
- 1. Collagens
Collagen is the most abundant protein in the human body, providing structural tensile strength:
Type I Collagen : Dominant collagen in dermis, bone, and tendon (~80% of normal adult skin). Provides high tensile strength.
Type III Collagen : Prevalent in embryonic tissue and early granulation tissue (~30% of early wound matrix). Thin and pliable.
Type IV Collagen : Key component of the epidermal basement membrane zone (anchors keratinocytes via hemidesmosomes).
Biochemical Requirement: Collagen synthesis requires hydroxylation of proline and lysine residues inside the endoplasmic reticulum. This reaction requires Vitamin C (ascorbic acid) , ferrous iron (Fe²⁺) , molecular oxygen (O₂) , and alpha-ketoglutarate . Scurvy (Vitamin C deficiency) results in un-hydroxylated collagen that cannot form stable triple helices, causing wound dehiscence.
2. Cell-Adhesive Glycoproteins
Fibronectin : Forms a molecular bridge connecting cell surface integrin receptors to structural collagen fibers, guiding cell migration into the wound bed.
Laminin : Primary non-collagenous protein of the basement membrane, essential for keratinocyte adhesion and differentiation.
3. Proteoglycans and Glycosaminoglycans (GAGs)
Hyaluronic Acid (HA) : A large, non-sulfated GAG that binds massive amounts of water. HA creates a hydrated, swollen matrix during early inflammation, facilitating cell movement and nutrient diffusion.
Proteoglycans (e.g., Decorin, Versican, Perlecan) : Protein cores with attached GAG chains that bind growth factors (acting as structural reservoirs) and regulate collagen fibrillogenesis.
3. MMPs vs. TIMPs Imbalance in Chronic Wounds
Normal tissue repair requires controlled matrix degradation to clear damaged tissue and allow remodeled collagen insertion. This balance is governed by Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases.
Matrix Metalloproteinases (MMPs)
MMPs are a family of zinc-dependent endopeptidases secreted as inactive zymogens (pro-MMPs) by neutrophils, macrophages, fibroblasts, and endothelial cells. They are activated extracellularly by proteolytic cleavage.
Collagenases (MMP-1, MMP-8) : Cleave native triple-helical Type I, II, and III collagens.
Gelatinases (MMP-2, MMP-9) : Degrade denatured collagen (gelatin), Type IV collagen, and fibronectin.
Stromelysins (MMP-3) : Broad substrate specificity; degrade proteoglycans, laminin, and activate other pro-MMPs.
Tissue Inhibitors of Metalloproteinases (TIMPs)
TIMPs (TIMP-1 through TIMP-4) are endogenous proteins secreted by tissue cells that bind covalently to active MMPs in a 1:1 stoichiometric ratio, rendering them enzymatically inactive.
Chronic Wound Pathophysiology: The MMP/TIMP Imbalance
In a healthy acute wound , MMP levels rise transiently to clear debris and allow cell migration, but are rapidly controlled by rising TIMP levels.
In a chronic non-healing wound :
Persistent bacterial bioburden and ischemia perpetuate an M1 macrophage and neutrophilic environment.
Pro-inflammatory cytokines ( TNF-α , IL-1β ) remain pathologically elevated.
MMP levels increase by 10- to 100-fold compared to acute wounds, while TIMP levels are suppressed or degraded . ACUTE WOUND (Balanced) CHRONIC WOUND (Imbalanced / Proteolytic)
- ┌─────────┐ ┌─────────┐ ┌──────────────────┐ ┌───────┐
- │ MMPs │ = │ TIMPs │ │ MMPs │ ≫ │ TIMPs │
- └─────────┘ └─────────┘ │ (10x-100x excess)│ └───────┘
- Controlled Remodeling └──────────────────┘
- │
- ▼
- Rapid ECM Degradation
- Growth Factor Destruction (PDGF/VEGF cleaved)
- Receptor Cleavage & Cell Senescence
- Stalled Wound Bed
Consequences of Excessive Proteolysis:
Rapid Degradation of ECM Scaffolding : Newly deposited fibronectin and collagen are destroyed before fibrillogenesis occurs.
Destruction of Growth Factors : Endogenous (and topically applied) PDGF, VEGF, and TGF-β are cleaved and inactivated within minutes by excess MMP-2, MMP-8, and MMP-9.
Inactivation of Cell Surface Receptors : Integrin receptors on fibroblasts and keratinocytes are cleaved, rendering cells unresponsive to local signaling cues (cellular senescence).
4. Comparison Table: Acute vs. Chronic Wound Fluid Environment
- Parameter / Component Acute Wound Fluid Chronic Non-Healing Wound Fluid
- MMP Activity Low / Transiently Controlled Pathologically Elevated (10x to 100x)
- TIMP Activity High / Counter-balanced Depressed or Enzymatically Degraded
- Pro-inflammatory Cytokines (TNF-α, IL-1β) Low / Resolving after Day 4 High / Persistently Elevated
- Intact Growth Factors (PDGF, VEGF) Abundant & Functional Cleaved & Inactivated
- Fibronectin Integrity Intact / High Molecular Weight Fragmented / Degraded
- Mitogenic Capacity Stimulates cell proliferation Inhibits proliferation / cytotoxic to cells
- 5. Clinical Management Strategies for CWS Practitioners
To restore a favorable ECM microenvironment in chronic wounds, CWS clinicians utilize targeted interventions:
Maintenance Debridement : Repeated sharp debridement removes senescent cells, bacterial biofilms, and tissue heavily laden with excess MMPs.
Advanced ECM Matrix Dressings : Application of collagen-based dressings (e.g., collagen/ORC—oxidized regenerated cellulose) acts as a sacrificial substrate, binding excess MMPs and preserving endogenous growth factors.
Bacterial Bioburden Control : Topical antimicrobials and targeted systemic antibiotics suppress cytokine-driven MMP production.